Document is current
Any future updates will be listed below
-
Authors
Reisman, Benjamin J.
Guo, Hui
Ramsey, Haley E.
Wright, Madison T.
Reinfeld, Bradley I.
Ferrell, P. Brent https://orcid.org/0000-0003-1140-9154
Sulikowski, Gary A.
Rathmell, W. Kimryn
Savona, Michael R.
Plate, Lars
Rubinstein, John L.
Bachmann, Brian O. https://orcid.org/0000-0001-5815-1176
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R01 GM092218, T32 GM065086, T32 GM065086, R35 GM133552)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA226833, F30 CA236131, F30 CA247202)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences
U.S. Department of Health & Human Services | NIH | National Cancer Institute
University of Toronto
National Science Foundation
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (K23 HL138291)
Gouvernement du Canada | Canadian Institutes of Health Research (PJT162186)
- License Information
-
More Information
Article History
Received: 17 May 2021
Accepted: 17 September 2021
First Online: 2 December 2021
Competing interests
: M.R.S. receives research funding from Astex, Incyte, Takeda and TG Therapeutics; has equity with Karyopharm; serves as an advisor or consultant to AbbVie, Astex, BMS, Celgene, Incyte, Karyopharm, Ryvu, Sierra Oncology, Takeda and TG Therapeutics. P.B.F. currently receives research funding from Incyte, and has received research funding from Astex and Forma Therapeutics in the past. Within the past 2 years, W.K.R. has received unrelated clinical research support Bristol-Meyers Squib, Merck, Pfizer, Peloton, Calithera and Incyte.
